Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $99.5 million.

  • Neurocrine Biosciences' Shares Outstanding (Weighted Average) fell 89.64% to $99.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $99.5 million, marking a year-over-year decrease of 89.64%. This contributed to the annual value of $99.5 million for FY2025, which is 89.64% down from last year.
  • As of Q4 2025, Neurocrine Biosciences' Shares Outstanding (Weighted Average) stood at $99.5 million, which was down 89.64% from $99.4 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Shares Outstanding (Weighted Average) registered a high of $101.1 million during Q3 2024, and its lowest value of $94.2 million during Q1 2021.
  • Its 4-year average for Shares Outstanding (Weighted Average) is $98.3 million, with a median of $99.3 million in 2025.
  • In the last 5 years, Neurocrine Biosciences' Shares Outstanding (Weighted Average) soared by 327.87% in 2024 and then tumbled by 168.15% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' Shares Outstanding (Weighted Average) (Quarter) stood at $94.7 million in 2021, then rose by 3.17% to $97.7 million in 2023, then rose by 2.76% to $100.4 million in 2024, then dropped by 0.9% to $99.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $99.5 million for Q4 2025, versus $99.4 million for Q3 2025 and $99.3 million for Q2 2025.